These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 32391636)

  • 1. Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.
    Li T; Song L; Zhang Y; Han Y; Zhan Z; Xv Z; Li Y; Tang Y; Yang Y; Wang S; Li S; Zheng L; Li Y; Gao Y
    J Cell Mol Med; 2020 Jun; 24(12):6704-6715. PubMed ID: 32391636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL.
    Li B; Li H; Bai Y; Kirschner-Schwabe R; Yang JJ; Chen Y; Lu G; Tzoneva G; Ma X; Wu T; Li W; Lu H; Ding L; Liang H; Huang X; Yang M; Jin L; Kang H; Chen S; Du A; Shen S; Ding J; Chen H; Chen J; von Stackelberg A; Gu L; Zhang J; Ferrando A; Tang J; Wang S; Zhou BB
    Nat Med; 2015 Jun; 21(6):563-71. PubMed ID: 25962120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
    Somazu S; Tanaka Y; Tamai M; Watanabe A; Kagami K; Abe M; Harama D; Shinohara T; Akahane K; Goi K; Sugita K; Moriyama T; Yang J; Goto H; Minegishi M; Iwamoto S; Takita J; Inukai T
    J Cell Mol Med; 2021 Nov; 25(22):10521-10533. PubMed ID: 34636169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9-Mediated Induction of Relapse-Specific
    Nguyen TTT; Tanaka Y; Sanada M; Hosaka M; Tamai M; Kagami K; Komatsu C; Somazu S; Harama D; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
    Mol Pharmacol; 2023 Apr; 103(4):199-210. PubMed ID: 36669880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiopurine Resistance in Childhood ALL Is Mediated by PRPS1 Mutations.
    Cancer Discov; 2015 Jul; 5(7):693. PubMed ID: 25998402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
    Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
    Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma.
    Gutiérrez MI; Bhatia K; Cherney B; Capello D; Gaidano G; Magrath I
    Ann Oncol; 1997 Oct; 8(10):987-94. PubMed ID: 9402172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins.
    Smith-Sørensen B; Hijmans EM; Beijersbergen RL; Bernards R
    J Biol Chem; 1996 Mar; 271(10):5513-8. PubMed ID: 8621409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
    Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
    Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of modified B-NHL-BFM-90 protocol on Burkitt's lymphoma in Chinese children and adolescents].
    Sun XF; Zhen ZJ; Liu DG; Xia Y; Xiang XJ; Chen XQ; Ling JY; Zheng L; Luo WB; Lin H; He YJ; Guan ZZ
    Ai Zheng; 2007 Dec; 26(12):1339-43. PubMed ID: 18076797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine.
    Murphy SB; Bowman WP; Abromowitch M; Mirro J; Ochs J; Rivera G; Pui CH; Fairclough D; Berard CW
    J Clin Oncol; 1986 Dec; 4(12):1732-9. PubMed ID: 3491184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
    Albert T; Urlbauer B; Kohlhuber F; Hammersen B; Eick D
    Oncogene; 1994 Mar; 9(3):759-63. PubMed ID: 8108117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
    Richter-Larrea JA; Robles EF; Fresquet V; Beltran E; Rullan AJ; Agirre X; Calasanz MJ; Panizo C; Richter JA; Hernandez JM; Roman-Gomez J; Prosper F; Martinez-Climent JA
    Blood; 2010 Oct; 116(14):2531-42. PubMed ID: 20570860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma.
    Boffa LC; Cutrona G; Cilli M; Mariani MR; Matis S; Pastorino M; Damonte G; Millo E; Roncella S; Ferrarini M
    Oligonucleotides; 2005; 15(2):85-93. PubMed ID: 15989423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma.
    Niklinski J; Claassen G; Meyers C; Gregory MA; Allegra CJ; Kaye FJ; Hann SR; Zajac-Kaye M
    Mol Cell Biol; 2000 Jul; 20(14):5276-84. PubMed ID: 10866684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shikonin exerts antitumor activity in Burkitt's lymphoma by inhibiting C-MYC and PI3K/AKT/mTOR pathway and acts synergistically with doxorubicin.
    Ni F; Huang X; Chen Z; Qian W; Tong X
    Sci Rep; 2018 Feb; 8(1):3317. PubMed ID: 29463831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia.
    Schwenn MR; Blattner SR; Lynch E; Weinstein HJ
    J Clin Oncol; 1991 Jan; 9(1):133-8. PubMed ID: 1985162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in the management of Burkitt's lymphoma.
    Levine AM
    Clin Lymphoma; 2002 Dec; 3 Suppl 1():S19-25. PubMed ID: 12521385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
    Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer.
    Cunningham JT; Moreno MV; Lodi A; Ronen SM; Ruggero D
    Cell; 2014 May; 157(5):1088-103. PubMed ID: 24855946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.